Phase 3 Trial Tests Evolocumab Safety in Children With Familial Hypercholesterolemia
An 80-week Amgen-sponsored Phase 3 trial evaluated evolocumab's safety and efficacy in pediatric patients aged 10–17 with inherited high LDL cholesterol.
Summary
Familial hypercholesterolemia is a genetic condition causing dangerously elevated LDL cholesterol from childhood, dramatically increasing the risk of early heart disease. This completed Phase 3 trial, sponsored by Amgen, tested whether evolocumab — a PCSK9 inhibitor already approved in adults — is safe and effective when added to standard therapy in children aged 10 to 17. Over 80 weeks of subcutaneous injections, researchers tracked safety, tolerability, and LDL-lowering efficacy in this younger population. The findings have important implications for how aggressively clinicians can treat inherited cholesterol disorders early in life, potentially preventing cardiovascular damage that accumulates silently over decades before adulthood.
Detailed Summary
Familial hypercholesterolemia affects approximately 1 in 250 people worldwide and is characterized by lifelong elevation of LDL cholesterol due to genetic mutations, most commonly in the LDL receptor pathway. Without adequate treatment, affected individuals face a dramatically accelerated risk of atherosclerosis and premature cardiovascular events, often beginning in their 30s and 40s. Identifying safe and effective therapies for pediatric patients is therefore a critical public health priority.
This Phase 3 clinical trial, sponsored by Amgen, evaluated the PCSK9 inhibitor evolocumab (AMG 145) specifically in children aged 10 to 17 diagnosed with familial hypercholesterolemia. Evolocumab works by blocking PCSK9, a protein that degrades LDL receptors, thereby allowing the liver to clear more LDL from the bloodstream. The drug is already approved for adult use, but pediatric data had been limited prior to this study.
Over an 80-week treatment period, participants received subcutaneous injections of evolocumab added to their existing standard-of-care regimen, which typically includes statins and lifestyle modification. The primary endpoint focused on safety and tolerability, with efficacy — particularly LDL cholesterol reduction — as a secondary focus. The trial has been completed, suggesting results are available, though full published outcomes were not accessible for this summary.
If evolocumab demonstrates a favorable safety profile in this age group, it could fundamentally change pediatric lipid management, offering a powerful add-on option for children who cannot achieve LDL targets on statins alone. Earlier and more aggressive LDL lowering is thought to reduce lifetime atherosclerotic burden significantly.
Caveats include the relatively small and specialized pediatric population, the industry sponsorship by Amgen, and the fact that long-term cardiovascular event data in children would require decades of follow-up beyond this trial's scope.
Key Findings
- Phase 3 trial tested evolocumab over 80 weeks in children aged 10–17 with familial hypercholesterolemia.
- Primary endpoint was safety and tolerability of subcutaneous evolocumab added to standard of care.
- PCSK9 inhibition offers a mechanistically potent LDL-lowering strategy beyond statins in pediatric patients.
- Earlier aggressive LDL lowering in FH may significantly reduce lifetime cardiovascular risk.
- Trial is completed, but full efficacy results require access to the published study report.
Methodology
This was a completed Phase 3, single-arm or controlled trial enrolling children aged 10–17 with familial hypercholesterolemia, sponsored by Amgen. Evolocumab was administered subcutaneously over 80 weeks as an add-on to existing standard-of-care therapy. Safety, tolerability, and LDL efficacy were assessed across the treatment period.
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registration only, as the full study data were not accessible. Efficacy outcomes, adverse event rates, and subgroup analyses cannot be reported without the full publication. Industry sponsorship by Amgen may introduce potential bias in trial design and reporting.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.